[go: up one dir, main page]

WO2004006937A3 - Novel pharmaceutical compositions based on 5-alpha-reductase inhibitors and uses of same - Google Patents

Novel pharmaceutical compositions based on 5-alpha-reductase inhibitors and uses of same Download PDF

Info

Publication number
WO2004006937A3
WO2004006937A3 PCT/FR2003/002237 FR0302237W WO2004006937A3 WO 2004006937 A3 WO2004006937 A3 WO 2004006937A3 FR 0302237 W FR0302237 W FR 0302237W WO 2004006937 A3 WO2004006937 A3 WO 2004006937A3
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
same
pharmaceutical compositions
reductase inhibitors
compositions based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2003/002237
Other languages
French (fr)
Other versions
WO2004006937A2 (en
Inventor
Jerome Besse
Laurence Besse
Brigitte Taravella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Besins International Belgique
Galenix Innovations Sas
Original Assignee
Besins International Belgique
Galenix Innovations Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins International Belgique, Galenix Innovations Sas filed Critical Besins International Belgique
Priority to AU2003269027A priority Critical patent/AU2003269027A1/en
Publication of WO2004006937A2 publication Critical patent/WO2004006937A2/en
Publication of WO2004006937A3 publication Critical patent/WO2004006937A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a pharmaceutical composition based on at least one 5-alpha-reductase inhibitor as an active substance, which is intended to be administered subcutaneously. The inventive composition is characterised in that it takes the form of a non-biodegradable implant and in that it enables the prolonged release of active substances.
PCT/FR2003/002237 2002-07-16 2003-07-15 Novel pharmaceutical compositions based on 5-alpha-reductase inhibitors and uses of same Ceased WO2004006937A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003269027A AU2003269027A1 (en) 2002-07-16 2003-07-15 Novel pharmaceutical compositions based on 5-alpha-reductase inhibitors and uses of same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0208964 2002-07-16
FR0208964A FR2842421B1 (en) 2002-07-16 2002-07-16 NOVEL PHARMACEUTICAL COMPOSITIONS BASED ON 5-ALPHA-REDUCTASE INHIBITORS AND USES THEREOF

Publications (2)

Publication Number Publication Date
WO2004006937A2 WO2004006937A2 (en) 2004-01-22
WO2004006937A3 true WO2004006937A3 (en) 2004-04-08

Family

ID=29797452

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/002237 Ceased WO2004006937A2 (en) 2002-07-16 2003-07-15 Novel pharmaceutical compositions based on 5-alpha-reductase inhibitors and uses of same

Country Status (3)

Country Link
AU (1) AU2003269027A1 (en)
FR (1) FR2842421B1 (en)
WO (1) WO2004006937A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1745796A1 (en) * 2005-07-19 2007-01-24 Bionorica Research GmbH Compound preparation for treating prostate carcinoma
KR101809908B1 (en) 2014-07-21 2018-01-25 주식회사 종근당 Pharmaceutical composition comprising 5-α reductase inhibitor
CN110638777A (en) * 2019-10-24 2020-01-03 仁和堂药业有限公司 Finasteride tablet and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08157370A (en) * 1994-12-06 1996-06-18 Banyu Pharmaceut Co Ltd Finasteride-containing sustained-release composition
WO1997030656A1 (en) * 1996-02-23 1997-08-28 The Population Council, Inc. Male contraceptive implant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08157370A (en) * 1994-12-06 1996-06-18 Banyu Pharmaceut Co Ltd Finasteride-containing sustained-release composition
WO1997030656A1 (en) * 1996-02-23 1997-08-28 The Population Council, Inc. Male contraceptive implant

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199634, Derwent World Patents Index; AN 1996-339087, XP002234801 *
T. ISOTALO ET AL.: "A double-blind, randomized, placebo-controlled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly L-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from benign prostatic hyperplasia", BJU INTERNATIONAL, vol. 88, no. 1, July 2001 (2001-07-01), Oxford (GB), pages 30 - 34, XP002234800 *

Also Published As

Publication number Publication date
FR2842421A1 (en) 2004-01-23
WO2004006937A2 (en) 2004-01-22
AU2003269027A8 (en) 2004-02-02
AU2003269027A1 (en) 2004-02-02
FR2842421B1 (en) 2004-10-15

Similar Documents

Publication Publication Date Title
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MXPA04004837A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
AU2003293555A1 (en) 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
WO2005067627A3 (en) Cosmetic composition and method for retarding hair growth
WO2007117706A3 (en) Solid oral dosage form containing an enhancer
WO2003080070A3 (en) Combination comprising an hmg-coa reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer
EP2338490A3 (en) Combinations useful for the treatment of neuronal disorders
TW200514772A (en) Novel tetrahydropyridine derivatives
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
TW200517106A (en) Sustained release pharmaceutical compositions
WO2005007115A3 (en) Pharmaceutical composition for inhibiting acid secretion
WO2008001325A3 (en) Herbal compositions for the treatment of diseases of the oral cavity
WO2004091497A3 (en) Methods and compositions for increasing the anaerobic working capacity in tissues
WO2004091645A3 (en) Composition comprising rosmarinic acid, borneol and ginsenoside
GB0209749D0 (en) Compositions and methods
WO2004113297A3 (en) Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
MY130792A (en) 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
WO2005065639A3 (en) Novel pharmaceutical compositions
WO2005054244A3 (en) Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain
WO2003035080A3 (en) A process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
WO2004006937A3 (en) Novel pharmaceutical compositions based on 5-alpha-reductase inhibitors and uses of same
WO2004078180A3 (en) Naaladase inhibitors for treating opioid tolerance

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP